Response to Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255
- Address correspondence to Guenther Boden, Temple University Health Science Center, General Clinical Research Center, 3401 North Broad St., 4W, Philadelphia, PA 19140-6148. E-mail: bodengh{at}tuhs.temple.edu
We agree with Drs. Karalliedde and Viberti (1) that our findings (2) are preliminary. First, we studied only a small number of patients. Moreover, our finding that therapy with rosiglitazone plus fenofibrate prevented the expected rosiglitazone-induced water retention was completely unanticipated and rather surprising. Clearly, therefore, this intriguing observation needs to be confirmed with a much larger number of patients and in much greater detail.
